Ken Griffin Bio Cardia, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$0.38 - $0.68 $8,702 - $15,572	-22,900 Reduced 57.11%	17,200 $7,000
Q4 2023 Feb 14, 2024	SELL	$0.37 - $1.07 $296 - $856	-800 Reduced 1.96%	40,100 $26,000
Q3 2023 Nov 14, 2023	BUY	$0.37 - $2.85 $5,513 - $42,465	14,900 Added 57.31%	40,900 $17,000
Q2 2023 Aug 14, 2023	SELL	$1.52 - $2.8 $81,168 - $149,520	-53,400 Reduced 67.25%	26,000 $69,000
Q1 2023 May 15, 2023	BUY	$1.87 - $2.54 $41,327 - $56,134	22,100 Added 38.57%	79,400 $154,000
Q4 2022 Feb 14, 2023	SELL	$1.61 - $32.1 $2,576 - $51,360	-1,600 Reduced 2.72%	57,300 $119,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $30.3 $4,272 - $539,340	17,800 Added 43.31%	58,900 $114,000

Ticker BCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,758,200
Market Cap $41.2M
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary di...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.